EGFR mutant-IN-2

EGFR mutant-IN-2 (D51) is a potent, selective inhibitor of EGFR triple mutants L858R/T790M/C797S and del19/T790M/C797S, with IC50 values of 14 nM and 62 nM, respectively. It demonstrates favorable pharmacokinetics, safety, and in vivo stability, supporting its use in preclinical research for studying resistant non-small cell lung cancer (NSCLC) models both in vitro and in vivo.